References
- Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharma Biotechnol 2008; 9:423 - 430
- Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073 - 1078
- Reichert JM. Monoclonal antibodies in the clinic. Nat Biotechnol 2001; 19:819 - 822
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov 2004; 3:711 - 716
- Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008; 22:315 - 329
- Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009; 1:56 - 66
- Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331 - 337
- King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54:6176 - 6185
- Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9:129 - 134
- Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641 - 648
- Harmsen MM, De Haard HJ. Properties, production and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77:13 - 22
- Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008; 8:600 - 608
- Zider A, Drakeman DL. The future of monoclonal antibody technology. mAbs 2010; 2:361 - 364
- Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767 - 774